| AU724294B2              (en)* | 1997-01-22 | 2000-09-14 | Eisai Inc. | Microparticles for delivery of nucleic acid | 
| US7052678B2              (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties | 
| EE04628B1              (et)* | 1997-09-29 | 2006-06-15 | Inhale Therapeutic Systems, Inc. | Perforeeritud mikrostruktuure sisaldav pulber ja meetod perforeeritud mikrostruktuure sisaldava mikroosakeste kompositsiooni ning pulbri valmistamiseks | 
| US6946117B1              (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers | 
| US6309623B1              (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers | 
| US6433040B1              (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use | 
| US20060165606A1              (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents | 
| US6565885B1              (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions | 
| GB9727102D0              (en)* | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use | 
| EP1089712B1              (fr)* | 1998-06-24 | 2003-05-02 | Advanced Inhalation Research, Inc. | Grandes particules poreuses emises par un inhalateur | 
| EP1273290A1              (fr)* | 1998-06-24 | 2003-01-08 | Advanced Inhalation Research, Inc. | Particules poreuses de grande taille émises par inhalateur | 
| US6956021B1              (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations | 
| EP1767195A3              (fr)* | 1998-08-25 | 2007-04-04 | Advanced Inhalation Research, Inc. | Formulations de protéines stables séchées par pulvérisation | 
| ES2289823T3              (es)* | 1998-08-25 | 2008-02-01 | Advanced Inhalation Research, Inc. | Formulaciones proteicas estables secadas por atomizacion. | 
| US7056504B1              (en) | 1998-08-27 | 2006-06-06 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase I and II | 
| EP1109919A2              (fr) | 1998-08-27 | 2001-06-27 | Massachusetts Institute Of Technology | Heparinases a conception rationnelle derivees de l'heparinase i et ii | 
| MA25590A1              (fr)* | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche | 
| CA2276066A1              (fr)* | 1999-03-11 | 2000-09-11 | Zycos Inc. | Microparticules pour diffusion d'un acide nucleique | 
| AU2005201927B2              (en)* | 1999-03-11 | 2008-08-21 | Eisai Inc. | Microparticles for delivery of nucleic acid | 
| AU4543200A              (en)* | 1999-04-16 | 2000-11-02 | Dittgen, Michael | Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones | 
| ATE289825T1              (de)* | 1999-04-21 | 2005-03-15 | 1355540 Ontario Inc | Methacoline oder histamine formulierungen zur feststellung von asthma | 
| US7412332B1              (en) | 1999-04-23 | 2008-08-12 | Massachusetts Institute Of Technology | Method for analyzing polysaccharides | 
| AU4450700A              (en)* | 1999-04-27 | 2000-11-10 | Eli Lilly And Company | Insulin crystals for pulmonary administration | 
| US6428769B1              (en)* | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration | 
| EP1175204A4              (fr)* | 1999-05-04 | 2006-05-31 | Aradigm Corp | Formulations d'aerosol et dispositifs destines a augmenter la libido chez la femme par l'administration aigue de testosterone | 
| US7258850B2              (en) | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction | 
| EP1180020B2              (fr)* | 1999-05-27 | 2009-06-24 | Acusphere, Inc. | Matrices medicamenteuses poreuses et procedes de fabrication associes | 
| US7919119B2              (en) | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof | 
| US6610317B2              (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof | 
| US6395300B1              (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof | 
| EP1642572A1              (fr)* | 1999-05-27 | 2006-04-05 | Acusphere, Inc. | Matrices médicamenteuses poreuses et procédés de fabrication associés | 
| US6858199B1              (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol | 
| FR2797398B1              (fr)* | 1999-08-11 | 2002-10-18 | Mainelab | Microparticules pour administration pulmonaire | 
| US7252840B1              (en) | 1999-08-25 | 2007-08-07 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles | 
| US6586008B1              (en)* | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying | 
| AU763041B2              (en)* | 1999-08-25 | 2003-07-10 | Alkermes, Inc. | Modulation of release from dry powder formulations | 
| EP1210069B1              (fr)* | 1999-08-25 | 2004-12-29 | Advanced Inhalation Research, Inc. | Grandes particules poreuses susceptibles d'etre obtenues par le sechage par atomisation et aptes a l'administration pulmonaire | 
| DE19962221A1              (de)* | 1999-10-01 | 2001-05-23 | Glatt Process Technology Gmbh | Dispersionen für Depotapplikationen | 
| FI20002217L              (fi)* | 1999-12-30 | 2001-07-01 | Orion Yhtymae Oyj | Inhalaatiopartikkelit | 
| US7229619B1              (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | 
| AU2002219944B2              (en) | 2000-11-28 | 2008-02-21 | Medimmune, Llc | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | 
| US6869789B2              (en) | 2000-03-08 | 2005-03-22 | Massachusetts Institute Of Technology | Heparinase III and uses thereof | 
| GB0008660D0              (en)* | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases | 
| MXPA02001323A              (es) | 2000-05-10 | 2004-07-16 | Alliance Pharma | Microgranulos con base fosfolipida para la liberacion de farmaco. | 
| US7871598B1              (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use | 
| AU2006200768B2              (en)* | 2000-05-10 | 2008-07-17 | Novartis Ag | Phosopholipid-based powders for drug delivery | 
| FR2809309B1              (fr)* | 2000-05-23 | 2004-06-11 | Mainelab | Microspheres a liberation prolongee pour administration injectable | 
| ATE378039T1              (de)* | 2000-06-27 | 2007-11-15 | Vectura Ltd | Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung | 
| AU2001269261B2              (en)* | 2000-06-27 | 2005-11-17 | Vectura Limited | Method of making particles for use in a pharmaceutical composition | 
| US7575761B2              (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics | 
| WO2002007705A1              (fr)* | 2000-07-20 | 2002-01-31 | Campina B.V. | Materiau support pour inhalation de poudre seche | 
| US20020106368A1              (en)* | 2000-07-28 | 2002-08-08 | Adrian Bot | Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same | 
| AU2001292618A1              (en) | 2000-09-12 | 2002-03-26 | Massachusetts Institute Of Technology | Methods and products related to low molecular weight heparin | 
| US6514482B1              (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system | 
| US6613308B2              (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system | 
| AU2440802A              (en) | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides | 
| US6818216B2              (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies | 
| US7179900B2              (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | 
| US6855493B2              (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | 
| ES2727425T3              (es) | 2000-12-12 | 2019-10-16 | Medimmune Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas | 
| EP1797902A3              (fr)* | 2000-12-29 | 2007-10-03 | Advanced Inhalation Research, Inc. | Particules à libération prolongée destinées à être inhalées | 
| JP2005504715A              (ja)* | 2000-12-29 | 2005-02-17 | アドバンスト  インハレーション  リサーチ,インコーポレイテッド | 持続放出特性を有する吸入用粒子 | 
| GB0107106D0              (en)* | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations | 
| JP2004528339A              (ja)* | 2001-04-26 | 2004-09-16 | ネクター  セラピューティクス | 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物 | 
| WO2002094240A1              (fr)* | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Administration de composes physiologiquement actifs par voie d'inhalation | 
| US7498019B2              (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route | 
| US7458374B2              (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound | 
| DK1389096T3              (da)* | 2001-05-24 | 2009-06-22 | Alexza Pharmaceuticals Inc | Indgivelse af opiater gennem en inhalationsrute | 
| US20070122353A1              (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits | 
| US7090830B2              (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits | 
| US7585493B2              (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use | 
| WO2002094242A1              (fr) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Administration de rizatriptan ou de zolmitriptan par voie d'inhalation | 
| US7766013B2              (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device | 
| JP2005503425A              (ja) | 2001-05-24 | 2005-02-03 | アレックザ  モレキュラー  デリヴァリー  コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 | 
| DE60230035D1              (de) | 2001-05-24 | 2009-01-08 | Alexza Pharmaceuticals Inc | Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation | 
| GB0120123D0              (en)* | 2001-08-17 | 2001-10-10 | Upperton Ltd | Preparation of microparticles | 
| EP2325193A3              (fr) | 2001-11-02 | 2012-05-02 | Insert Therapeutics, Inc. | Procédés et compositions permettant l'utilisation thérapeutique de l'interférence ARN | 
| WO2003041693A1              (fr) | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Administration de diazepam a travers une voie pulmonaire | 
| DK1455755T3              (da) | 2001-11-20 | 2013-07-15 | Civitas Therapeutics Inc | Forbedrede partikelsammensætning til levering i lunge | 
| JP2005511629A              (ja)* | 2001-11-20 | 2005-04-28 | アドバンスト  インハレーション  リサーチ,インコーポレイテッド | 持続作用生成物送達用組成物 | 
| EP1446102A1              (fr) | 2001-11-21 | 2004-08-18 | Alexza Molecular Delivery Corporation | Delivrance de cafeine par voie inhalee | 
| ATE508735T1              (de) | 2001-12-19 | 2011-05-15 | Novartis Ag | Pulmonale verabreichung von aminoglykosiden | 
| AU2003206433A1              (en)* | 2002-02-15 | 2003-09-04 | Pantarhei Bioscience B.V. | A pulmonary drug delivery composition containing a progestogen and an androgen for use in a contraceptive method in males | 
| AU2003206434A1              (en)* | 2002-02-15 | 2003-09-04 | Pantarhei Bioscience B.V. | Pulmonary administration of 6-alpha-alkylated testosterone derivatives for androgen replacement therapy | 
| ES2609482T3              (es) | 2002-03-20 | 2017-04-20 | Civitas Therapeutics, Inc. | Administración pulmonar de levodopa | 
| AU2003243191B2              (en)* | 2002-05-02 | 2007-09-20 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections | 
| US9339459B2              (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials | 
| US7132100B2              (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations | 
| US7425618B2              (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations | 
| ES2381617T5              (es) | 2002-08-14 | 2016-02-24 | Macrogenics, Inc. | Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso | 
| CN1694689A              (zh)* | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 | 
| US7550133B2              (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them | 
| SG176314A1              (en) | 2002-12-31 | 2011-12-29 | Altus Pharmaceuticals Inc | Human growth hormone crystals and methods for preparing them | 
| ZA200505306B              (en)* | 2002-12-31 | 2006-09-27 | Altus Pharmaceuticals Inc | Complexes of protein crystals and ionic polymers | 
| JP2006524039A              (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 | 
| AU2004204817C1              (en) | 2003-01-13 | 2011-01-20 | Macrogenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof | 
| WO2004067601A1              (fr)* | 2003-01-31 | 2004-08-12 | Zeon Corporation | Composition polymerisable, composition de resine thermoplastique, resine reticulee, et materiaux composites a base de resine reticulee | 
| DE10303974A1              (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung | 
| US7354584B2              (en) | 2003-04-11 | 2008-04-08 | Medimmune, Inc. | Recombinant IL-9 antibodies | 
| CN102688224A              (zh)* | 2003-04-14 | 2012-09-26 | 维克特拉有限公司 | 用于提高剂量效率的药物组合物和装置 | 
| AU2004228757A1              (en)* | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | 
| WO2004103348A2              (fr)* | 2003-05-19 | 2004-12-02 | Baxter International Inc. | Preparations pharmaceutiques de petites particules d'anticonvulsivants et d'agents contre la demence et agents immmunosupresseurs | 
| AU2003252493A1              (en)* | 2003-07-09 | 2005-01-28 | Anges Mg, Inc. | Pharmaceutical composition containing decoy and method of using the same | 
| WO2005042743A2              (fr) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanisation d'anticorps | 
| DE10339197A1              (de)* | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität | 
| JP2006199589A              (ja)* | 2003-09-03 | 2006-08-03 | Ltt Bio-Pharma Co Ltd | 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 | 
| JP2005206491A              (ja)* | 2004-01-21 | 2005-08-04 | Medgel Corp | 肺気腫を治療するための経肺投与用製剤 | 
| ITMI20040795A1              (it) | 2004-04-23 | 2004-07-23 | Eratech S R L | Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa | 
| EP1742619A2              (fr)* | 2004-05-07 | 2007-01-17 | The President and Fellows of Harvard College | Vaccin pulmonaire contre le paludisme | 
| US7723306B2              (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation | 
| US7727962B2              (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation | 
| US7611709B2              (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives | 
| US7540286B2              (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols | 
| WO2006022714A1              (fr) | 2004-08-12 | 2006-03-02 | Alexza Pharmaceuticals, Inc. | Dispositif de distribution de drogue par aérosol intégrant des conditionnements thermiques actionnés par percussion | 
| JP2008513540A              (ja) | 2004-09-21 | 2008-05-01 | メディミューン,インコーポレーテッド | 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法 | 
| GB0425758D0              (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions | 
| JP2008523829A              (ja)* | 2004-12-22 | 2008-07-10 | ノボザイムス  アクティーゼルスカブ | 血清アルブミンの組換え生成 | 
| KR100891595B1              (ko) | 2005-02-28 | 2009-04-03 | 주식회사 케이티앤지 | 혈액 단백질의 삼출을 감소시키는 조성물 | 
| EP1869192B1              (fr) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Rearrangement de l'infrastructure d'anticorps | 
| DK1866414T3              (da) | 2005-03-31 | 2012-04-23 | Calando Pharmaceuticals Inc | Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf. | 
| EP3479844B1              (fr) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Dianticorps covalents et leurs utilisations | 
| US8859585B2              (en) | 2005-05-25 | 2014-10-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scopolamine for the treatment of depression and anxiety | 
| EP1893647A2              (fr) | 2005-06-23 | 2008-03-05 | MedImmune, Inc. | Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises | 
| US8217147B2              (en) | 2005-08-10 | 2012-07-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same | 
| US7612181B2              (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof | 
| EP2500357A3              (fr) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Immunoglobuline à double domaine variable et ses utilisations | 
| EP2495257A3              (fr) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Immunoglobuline à double domaine variable et ses utilisations | 
| ES2542501T3              (es) | 2005-09-30 | 2015-08-06 | Abbvie Deutschland Gmbh & Co Kg | Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso | 
| EP1951737A4              (fr) | 2005-11-01 | 2009-07-01 | Alnylam Pharmaceuticals Inc | Inhibition de la replication du virus de la grippe par interference arn | 
| EP1954246A4              (fr)* | 2005-11-11 | 2012-01-18 | Biolab Sanus Farmaceutica Ltda | Composition pharmaceutique solide comprenant des nanoparticles d agglomerat et leur procede de production | 
| EP1954718B1              (fr) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anticorps anti-globulomere a , fractions de liaison aux antigenes de ceux-ci, hydridomes , acides nucleiques, vecteurs, cellules hotes correspondants, procedes de production des anticorps, compositions comprenant les anticorps, utilisations des anticorps et procedes d'utilisation de ces anticorps | 
| US8497072B2              (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies | 
| CA2640165A1              (fr)* | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin | Procede de production de microparticules poreuses | 
| WO2007109097A2              (fr) | 2006-03-16 | 2007-09-27 | Alnylam Pharmaceuticals, Inc. | modulation ARNi des TGF-beta et usages therapeutiques | 
| GB0605723D0              (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes | 
| JP2007284362A              (ja)* | 2006-04-13 | 2007-11-01 | Tokyo Univ Of Science | 薬物送達粒子及びその製造方法 | 
| JP2009537153A              (ja) | 2006-05-19 | 2009-10-29 | アルニラム  ファーマシューティカルズ,  インコーポレイテッド | AhaのRNAi調節およびその治療上の使用 | 
| EP2505209A1              (fr) | 2006-06-26 | 2012-10-03 | MacroGenics, Inc. | Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés | 
| CA2661782C              (fr) | 2006-08-28 | 2019-04-16 | La Jolla Institute For Allergy And Immunology | Anticorps monoclonaux humains anti-hlight humain | 
| BRPI0716438B1              (pt) | 2006-09-08 | 2022-01-25 | Abbvie Bahamas Ltd | Proteínas de ligação a il-13, anticorpo anti-il-13 recombinante, construto de anticorpo, composições farmacêuticas e usos dos mesmos para reduzir a atividade e função biológica da il-13 e tratar distúrbios respiratórios | 
| JP2010506842A              (ja) | 2006-10-16 | 2010-03-04 | メディミューン,エルエルシー | 半減期が短縮された分子、その組成物および使用 | 
| US8455626B2              (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies | 
| US8895004B2              (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses | 
| WO2008112661A2              (fr) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Unité chauffante à utiliser dans un dispositif d'administration de médicament | 
| EP2164868B1              (fr) | 2007-05-04 | 2015-03-25 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Domaines variables transgéniques d'anticorps de lapin et leurs utilisations | 
| EP1997830A1              (fr) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | Molécules à liaison spécifiques RSV et leur moyen de fabrication | 
| CN101821288A              (zh) | 2007-06-21 | 2010-09-01 | 宏观基因有限公司 | 共价双抗体及其用途 | 
| AU2008282218A1              (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof | 
| KR100845009B1              (ko)* | 2007-08-07 | 2008-07-08 | 한국생명공학연구원 | 전하를 띠는 물질이 고착된 다공성 고분자 입자 및 그제조방법 | 
| EP2077132A1              (fr) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispositif distributeur, dispositif de stockage et procédé pour la distribution d'une formulation | 
| JP2011509675A              (ja) | 2008-01-18 | 2011-03-31 | メディミューン,エルエルシー | 部位特異的コンジュゲーションのためのシステイン操作抗体 | 
| US8962803B2              (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof | 
| JP2011516065A              (ja) | 2008-04-04 | 2011-05-26 | カランド  ファーマシューティカルズ,  インコーポレイテッド | Epas1阻害剤の組成物および使用 | 
| CA2722466A1              (fr) | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Immunoglobulines a double domaine variable et utilisations | 
| CA2723219A1              (fr) | 2008-05-09 | 2009-11-12 | Abbott Gmbh & Co. Kg | Anticorps contre le recepteur des produits terminaux de glycation avancee (rage) et leurs utilisations | 
| NZ589436A              (en) | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof | 
| RU2010153580A              (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двумя вариабельными доменами и их применение | 
| WO2009150136A1              (fr)* | 2008-06-09 | 2009-12-17 | Boehringer Ingelheim International Gmbh | Nouvelles particules à principe actif incorporé pour inhalation | 
| CN104829718A              (zh) | 2008-07-08 | 2015-08-12 | 艾伯维公司 | 前列腺素e2结合蛋白及其用途 | 
| CN102149825B              (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 | 
| CN106432503B              (zh) | 2008-12-19 | 2020-03-06 | 宏观基因有限公司 | 共价双抗体及其用途 | 
| US8852608B2              (en) | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus | 
| US8030026B2              (en) | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof | 
| WO2010102065A1              (fr) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Compositions pharmaceutiques de dérivés de polymère de dextrane | 
| MX2011009362A              (es) | 2009-03-05 | 2011-09-26 | Abbott Lab | Proteinas de union a il-17. | 
| US8283162B2              (en) | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof | 
| WO2010111132A2              (fr) | 2009-03-27 | 2010-09-30 | Bend Research, Inc. | Procédé de séchage par pulvérisation | 
| JP5670421B2              (ja) | 2009-03-31 | 2015-02-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | コンポーネント表面のコーティング方法 | 
| JP5763053B2              (ja) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アダプタ、吸入器具及びアトマイザ | 
| US20120134984A1              (en) | 2009-06-01 | 2012-05-31 | Olga Lubman | Molecules with extended half-lives and uses thereof | 
| JP5918129B2              (ja) | 2009-06-22 | 2016-05-18 | メディミューン,エルエルシー | 部位特異的共役のための操作されたFc領域 | 
| IN2012DN01328A              (fr) | 2009-08-13 | 2015-06-05 | Crucell Holland Bv |  | 
| CN102741288B              (zh) | 2009-08-29 | 2015-08-19 | Abbvie公司 | 治疗用dll4结合蛋白 | 
| CN102612524A              (zh) | 2009-09-01 | 2012-07-25 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 | 
| WO2011035205A2              (fr) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation | 
| US8568726B2              (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule | 
| DK2486141T3              (en) | 2009-10-07 | 2018-04-23 | Macrogenics Inc | FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE | 
| WO2011047262A2              (fr) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Immunoglobulines à deux domaines variables et utilisations afférentes | 
| UY32979A              (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas | 
| TW201121568A              (en) | 2009-10-31 | 2011-07-01 | Abbott Lab | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof | 
| US10016568B2              (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer | 
| AP3141A              (en) | 2009-11-25 | 2015-02-28 | Boehringer Ingelheim Int | Nebulizer | 
| EP2504051B1              (fr) | 2009-11-25 | 2019-09-04 | Boehringer Ingelheim International GmbH | Nébuliseur | 
| DK2510001T3              (en) | 2009-12-08 | 2016-02-29 | Abbvie Deutschland | MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER | 
| US9028797B2              (en) | 2010-02-26 | 2015-05-12 | Nagasaki University | Composite body for antigen or drug delivery | 
| CN105037543B              (zh) | 2010-03-02 | 2020-11-03 | Abbvie 公司 | 治疗性dll4结合蛋白 | 
| WO2011116090A1              (fr) | 2010-03-17 | 2011-09-22 | Abbott Research B.V. | Composition d'anticorps anti-facteur de croissance nerveux (ngf) | 
| US8987419B2              (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins | 
| EP3345926B1              (fr) | 2010-05-06 | 2023-04-05 | Novartis AG | Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6) | 
| US9290573B2              (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies | 
| PE20130205A1              (es) | 2010-05-14 | 2013-03-24 | Abbvie Inc | Proteinas de union a il-1 | 
| US9943654B2              (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer | 
| ES2690760T3              (es) | 2010-06-25 | 2018-11-22 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Polipéptido de flagelina como agonista de TLR5 para su uso en el tratamiento de infecciones de las vías respiratorias | 
| US20120009196A1              (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein | 
| EP2591000B1              (fr) | 2010-07-09 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Anticorps anti-virus respiratoire syncytial (rsv) humain et procédés d'utilisation | 
| UY33492A              (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas | 
| US9120862B2              (en) | 2010-07-26 | 2015-09-01 | Abbott Laboratories | Antibodies relating to PIVKA-II and uses thereof | 
| ES2667100T3              (es) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos | 
| KR20130100118A              (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 | 
| EP3533803B1              (fr) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anticorps anti-bêta-amyloïde | 
| ES2910305T3              (es) | 2010-08-19 | 2022-05-12 | Zoetis Belgium S A | Anticuerpos anti-NGF y su uso | 
| GB201013989D0              (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same | 
| PL2606070T4              (pl) | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) | 
| GB201014122D0              (en)* | 2010-08-24 | 2010-10-06 | Univ Gent | Particulate biologic drug delivery system | 
| RU2013113225A              (ru) | 2010-08-26 | 2014-10-10 | Эббви Инк. | Иммуноглобулины с двумя вариабельными доменами и их применение | 
| EP2611530B1              (fr) | 2010-09-03 | 2019-01-16 | Bend Research, Inc. | Appareil de séchage par atomisation et procédés d'utilisation de cet appareil | 
| PT2611529T              (pt) | 2010-09-03 | 2019-05-09 | Bend Res Inc | Método de secagem por pulverização | 
| US9248584B2              (en) | 2010-09-24 | 2016-02-02 | Bend Research, Inc. | High-temperature spray drying process and apparatus | 
| JP2014504260A              (ja)* | 2010-10-15 | 2014-02-20 | グラクソ  グループ  リミテッド | 集合ナノ粒子状薬物製剤、その製造及び使用 | 
| US20130245233A1              (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules | 
| US20120275996A1              (en) | 2010-12-21 | 2012-11-01 | Abbott Laboratories | IL-1 Binding Proteins | 
| WO2012121775A2              (fr) | 2010-12-21 | 2012-09-13 | Abbott Laboratories | Immunoglobulines à double domaine variable et leurs utilisations | 
| WO2012130757A1              (fr) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Appareil médical pourvu d'un récipient | 
| KR101970025B1              (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들 | 
| US9084727B2              (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces | 
| JP6145088B2              (ja) | 2011-05-21 | 2017-06-07 | マクロジェニクス,インコーポレーテッド | 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用 | 
| US9827384B2              (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer | 
| HK1198328A1              (zh) | 2011-07-13 | 2015-04-02 | Abbvie Inc. | 使用抗il-13抗體治療哮喘的方法和組合物 | 
| EP2731970B1              (fr) | 2011-07-15 | 2018-11-28 | MorphoSys AG | Anticorps à réaction croisée pour le facteur d'inhibition de la migration des macrophages et la d-dopachrome tautomérase | 
| US9676854B2              (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses | 
| CA2853258A1              (fr) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Agents de liaison immunologique diriges contre la sclerostine | 
| AU2012349736A1              (en) | 2011-12-05 | 2014-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3 | 
| UY34487A              (es) | 2011-12-05 | 2013-07-31 | Novartis Ag | Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3) | 
| CA2855840C              (fr) | 2011-12-14 | 2023-08-29 | AbbVie Deutschland GmbH & Co. KG | Composition et methode pour le diagnostic et le traitement de troubles lies au fer | 
| WO2013090633A2              (fr) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition et méthode pour le diagnostic et le traitement de troubles liés au fer | 
| ES3027182T3              (en) | 2011-12-23 | 2025-06-13 | Pfizer | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor | 
| CN104159920A              (zh) | 2011-12-30 | 2014-11-19 | 艾伯维公司 | 针对il-13和/或il-17的双重可变结构域免疫球蛋白 | 
| MX352772B              (es) | 2012-01-27 | 2017-12-07 | Abbvie Deutschland | Composición y método para el diagnóstico y tratamiento de enfermedades asociadas con la degeneración de neuritas. | 
| KR20140147891A              (ko) | 2012-04-13 | 2014-12-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 응집체 입자 | 
| WO2013152894A1              (fr) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Pulvérisateur comprenant des moyens de détrompage | 
| US9827191B2              (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications | 
| US11596599B2              (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications | 
| CA2871745C              (fr) | 2012-05-03 | 2023-01-24 | Kala Pharmaceuticals, Inc. | Nanoparticules pharmaceutiques presentant un transport muqueux ameliore | 
| KR102310775B1              (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 | 
| JP6321633B2              (ja) | 2012-06-04 | 2018-05-09 | ノバルティス アーゲー | 部位特異的標識法およびそれによって生成される分子 | 
| CN104364264B              (zh) | 2012-06-06 | 2018-07-24 | 硕腾服务有限责任公司 | 犬源化抗ngf抗体和其方法 | 
| TW201402608A              (zh) | 2012-07-12 | 2014-01-16 | Abbvie Inc | Il-1結合蛋白質 | 
| AU2013290616B2              (en) | 2012-07-19 | 2016-03-10 | Adamis Pharmaceuticals Corporation | Powder feeding apparatus | 
| WO2014071074A2              (fr) | 2012-11-01 | 2014-05-08 | Abbvie Inc. | Immunoglobulines à domaine variable double anti-vegf/dll4 et leurs utilisations | 
| EP2917237A1              (fr) | 2012-11-09 | 2015-09-16 | Pfizer Inc. | Anticorps spécifiques du facteur de croissance b dérivé des plaquettes, leurs compositions et leurs utilisations | 
| CA2894689A1              (fr) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | Anticorps anti-b7-h4 humain et leurs utilisations | 
| US9790277B2              (en) | 2012-12-21 | 2017-10-17 | The Johns Hopkins University | Anti-H7CR antibodies | 
| KR20150139830A              (ko) | 2013-02-01 | 2015-12-14 | 글리아로직스 인코포레이티드 | 신경변성 및 기타 질환의 치료를 위한 조성물 및 방법 | 
| SG10201706468RA              (en) | 2013-02-08 | 2017-09-28 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates | 
| WO2014124258A2              (fr) | 2013-02-08 | 2014-08-14 | Irm Llc | Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués | 
| AU2014216178B2              (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof | 
| ES2831625T3              (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos | 
| US9688688B2              (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof | 
| US9498532B2              (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates | 
| JP6505076B2              (ja) | 2013-03-14 | 2019-04-24 | アボット・ラボラトリーズAbbott Laboratories | Hcv抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物 | 
| EP3564384A1              (fr) | 2013-03-14 | 2019-11-06 | Abbott Laboratories | Anticorps monoclonaux à domaine de liaison à un lipide du noyau de vhc | 
| EP3611189A1              (fr) | 2013-03-14 | 2020-02-19 | Novartis AG | Anticorps dirigés contre notch 3 | 
| MX2015012824A              (es) | 2013-03-14 | 2016-06-24 | Abbott Lab | Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos. | 
| TW201512219A              (zh) | 2013-03-15 | 2015-04-01 | Abbvie Inc | 針對IL-1β及/或IL-17之雙特異性結合蛋白 | 
| CN105007950B              (zh) | 2013-03-15 | 2019-01-15 | 诺华股份有限公司 | 抗体药物缀合物 | 
| US9469686B2              (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same | 
| SG11201509618QA              (en) | 2013-05-24 | 2015-12-30 | Medimmune Llc | Anti-b7-h5 antibodies and their uses | 
| WO2014194293A1              (fr) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Méthodes améliorées de sélection de patients pouvant être soumis à des thérapies ciblant pd-1 ou b7-h4, et polythérapies associées | 
| EP3003390B1              (fr) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anticorps anti-c10orf54 et leurs utilisations | 
| EP3003372B1              (fr) | 2013-06-07 | 2019-10-09 | Duke University | Inhibiteurs du facteur h du complément | 
| EP2835146B1              (fr) | 2013-08-09 | 2020-09-30 | Boehringer Ingelheim International GmbH | Atomiseur | 
| UA116479C2              (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ | 
| US11384149B2              (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof | 
| WO2015018904A1              (fr) | 2013-08-09 | 2015-02-12 | Boehringer Ingelheim International Gmbh | Nébuliseur | 
| EP2839842A1              (fr) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations | 
| EP2840091A1              (fr) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation | 
| WO2015039212A1              (fr) | 2013-09-17 | 2015-03-26 | University Health Network (Uhn): Technology Development And Commercialization | Agents dirigés contre une interaction cis rgma/néogénine ou contre les radeaux lipidiques et utilisation de ceux-ci dans des méthodes thérapeutiques | 
| US10287572B2              (en) | 2013-11-01 | 2019-05-14 | Regents Of The University Of Minnesota | Protein scaffolds and methods of use | 
| CN106061261B              (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 | 
| US9890173B2              (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof | 
| PE20161092A1              (es) | 2013-11-13 | 2016-10-28 | Pfizer | Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y uso de ellos | 
| CA2931978A1              (fr) | 2013-12-02 | 2015-06-11 | Abbvie Inc. | Compositions et methodes pour traiter l'arthrose | 
| WO2015109212A1              (fr) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anticorps anti-il-2 et compositions et utilisations de ceux-ci | 
| WO2015110930A1              (fr) | 2014-01-24 | 2015-07-30 | Pfizer Inc. | Protéines de récepteur d'interleukine 21 modifiées | 
| PT3104854T              (pt) | 2014-02-10 | 2020-06-26 | Respivant Sciences Gmbh | Estabilizadores de mastócitos para tratamento de doença pulmonar | 
| JP2017510624A              (ja) | 2014-02-10 | 2017-04-13 | パタラ ファーマ リミテッド ライアビリティ カンパニー | 肥満細胞安定剤による全身性障害の治療 | 
| BR112016018754A2              (pt) | 2014-02-14 | 2017-10-10 | S Chi Andrew | método de tratamento de um câncer com vascularização | 
| JP6870988B2              (ja) | 2014-02-24 | 2021-05-19 | セルジーン コーポレイション | 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法 | 
| GB201403775D0              (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods | 
| US20150291689A1              (en) | 2014-03-09 | 2015-10-15 | Abbvie, Inc. | Compositions and Methods for Treating Rheumatoid Arthritis | 
| EP3960767A3              (fr) | 2014-03-12 | 2022-06-01 | Novartis AG | Sites spécifiques utilisables pour la modification d'anticorps en vue de l'obtention d'immunoconjugués | 
| SG11201607746QA              (en) | 2014-03-21 | 2016-10-28 | Abbvie Inc | Anti-egfr antibodies and antibody drug conjugates | 
| JP6580070B2              (ja) | 2014-05-07 | 2019-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 容器、ネブライザ、及び使用 | 
| FI3928818T3              (fi) | 2014-05-07 | 2023-05-03 | Boehringer Ingelheim Int | Nebulisaattori ja säiliö | 
| HUE055604T2              (hu) | 2014-05-07 | 2021-12-28 | Boehringer Ingelheim Int | Porlasztó | 
| CN106413750B              (zh) | 2014-05-16 | 2022-04-29 | 免疫医疗有限责任公司 | 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子 | 
| ES2890079T3              (es) | 2014-05-29 | 2022-01-17 | Macrogenics Inc | Moléculas de unión triespecíficas y métodos de uso de las mismas | 
| TWI693232B              (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 | 
| JP6755235B2              (ja) | 2014-07-16 | 2020-09-16 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 低悪性度漿液性癌におけるher3阻害 | 
| WO2016020791A1              (fr) | 2014-08-05 | 2016-02-11 | Novartis Ag | Conjugués anticorps ckit-médicament | 
| CA2954599A1              (fr) | 2014-08-12 | 2016-02-18 | Novartis Ag | Conjugues medicament-anticorps anti-cdh6 | 
| JP6839075B2              (ja) | 2014-09-26 | 2021-03-03 | マクロジェニクス,インコーポレーテッド | Cd19及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用 | 
| MA40910A              (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire | 
| KR102693806B1              (ko) | 2014-12-11 | 2024-08-09 | 피에르 파브르 메디카먼트 | 항-c10orf54 항체들 및 그들의 용도들 | 
| US10093733B2              (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins | 
| CN108367003B              (zh) | 2014-12-12 | 2022-01-21 | 麻省总医院 | 乳腺癌脑转移的治疗 | 
| TW201639596A              (zh) | 2015-01-24 | 2016-11-16 | 艾伯維有限公司 | 用於治療牛皮癬性關節炎之組合物及方法 | 
| US10501552B2              (en) | 2015-01-26 | 2019-12-10 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains | 
| TW201632202A              (zh) | 2015-01-30 | 2016-09-16 | 諾華公司 | 乳癌之治療 | 
| DE112016001013T5              (de) | 2015-03-03 | 2017-12-21 | Kymab Limited | Antikörper, verwendungen und verfahren | 
| DK3303395T3              (da) | 2015-05-29 | 2020-01-27 | Abbvie Inc | Anti-cd40-antistoffer og anvendelser deraf | 
| TWI773646B              (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 | 
| TW201710286A              (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 | 
| WO2016203432A1              (fr) | 2015-06-17 | 2016-12-22 | Novartis Ag | Conjugués anticorps-médicament | 
| EP3325010B1              (fr) | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Anticorps anti-facteur de coagulation xia et leurs utilisations | 
| TWI762879B              (zh) | 2015-07-30 | 2022-05-01 | 美商宏觀基因股份有限公司 | Pd-1結合分子和其使用方法 | 
| US10265296B2              (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders | 
| US10238625B2              (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers | 
| EP4324476A3              (fr) | 2015-09-11 | 2024-05-01 | AbbVie Inc. | Méthodes de traitement de formes récurrentes de la sclérose en plaques | 
| US9862760B2              (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies | 
| RU2731202C2              (ru) | 2015-10-08 | 2020-08-31 | Макродженикс, Инк. | Комбинированная терапия для лечения рака | 
| CA2946113A1              (fr) | 2015-10-23 | 2017-04-23 | Pfizer Inc. | Anticorps anti-il-2 et leurs compositions et methodes d'utilisation | 
| MA44334A              (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll | 
| JP7227007B2              (ja) | 2015-12-02 | 2023-02-21 | ストサイエンシス, インコーポレイテッド | グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体 | 
| ES2861449T3              (es) | 2015-12-02 | 2021-10-06 | Stcube & Co Inc | Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos | 
| EP3389714A4              (fr) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation | 
| WO2017125897A1              (fr) | 2016-01-21 | 2017-07-27 | Novartis Ag | Molécules multispécifiques ciblant cll-1 | 
| UY37127A              (es) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas | 
| PE20231049A1              (es) | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso | 
| WO2017180813A1              (fr) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Nouvelles molécules de liaison à b7-h3, leurs conjugués anticorps-médicaments et leurs procédés d'utilisation | 
| BR112018074966A2              (pt) | 2016-06-01 | 2019-03-12 | AbbVie Deutschland GmbH & Co. KG | anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor | 
| EP4364754A3              (fr) | 2016-06-08 | 2025-02-12 | AbbVie Inc. | Anticorps anti-b7-h3 et conjugués anticorps-médicament | 
| CN109563167A              (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 | 
| MX2018015274A              (es) | 2016-06-08 | 2019-10-07 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | 
| WO2017220989A1              (fr) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 et cytokines il-2 | 
| US20200148750A1              (en) | 2016-07-21 | 2020-05-14 | Emory University | Ebola Virus Antibodies and Binding Agents Derived Therefrom | 
| AU2017321495A1              (en) | 2016-08-31 | 2019-03-21 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis | 
| CA3036336A1              (fr) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Formes cristallines de composes therapeutiques et leurs utilisations | 
| EP3509423A4              (fr) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | Formes cristallines de composés thérapeutiques et leurs utilisations | 
| JP2019533641A              (ja) | 2016-09-08 | 2019-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態およびその使用 | 
| WO2018067341A1              (fr) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Compositions à base de cromolyne pour le traitement d'une fibrose pulmonaire | 
| US20180110760A1              (en) | 2016-10-21 | 2018-04-26 | Glialogix, Inc. | Compositions and methods for the treatmentof neurodegenerative and other diseases | 
| EP3534947A1              (fr) | 2016-11-03 | 2019-09-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés | 
| US10899842B2              (en) | 2016-11-23 | 2021-01-26 | Immunoah Therapeutics, Inc. | 4-1BB binding proteins and uses thereof | 
| JP2020513418A              (ja) | 2016-12-13 | 2020-05-14 | エモリー ユニバーシティ | ウイルス感染を管理するためのポリペプチド | 
| CN110234348B              (zh) | 2016-12-16 | 2024-06-25 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 | 
| JOP20190155A1              (ar) | 2016-12-21 | 2019-06-23 | Novartis Ag | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم | 
| IL267589B2              (en) | 2016-12-23 | 2024-11-01 | Macrogenics Inc | Adam9-binding molecules, and methods of use thereof | 
| WO2018138297A1              (fr) | 2017-01-27 | 2018-08-02 | Kymab Limited | Anticorps anti-opg | 
| JOP20190187A1              (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 | 
| WO2018185618A1              (fr) | 2017-04-03 | 2018-10-11 | Novartis Ag | Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement | 
| CA3064697A1              (fr) | 2017-04-19 | 2018-10-25 | Bluefin Biomedicine, Inc. | Anticorps anti-vtcn1 et conjugues anticorps-medicament | 
| AR111651A1              (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación | 
| US10865238B1              (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies | 
| KR20250036941A              (ko) | 2017-05-31 | 2025-03-14 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 | 
| EP3630834A1              (fr) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Méthodes de traitement du cancer à l'aide d'anticorps et de molécules se liant de manière immunospécifique à btn1a1 | 
| KR20250097991A              (ko) | 2017-06-06 | 2025-06-30 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법 | 
| CN110997725B              (zh) | 2017-06-12 | 2024-08-09 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 | 
| CN111615520A              (zh) | 2017-12-01 | 2020-09-01 | 辉瑞大药厂 | 抗cxcr5抗体及其组合物和用途 | 
| WO2019106578A2              (fr) | 2017-12-01 | 2019-06-06 | Novartis Ag | Anticorps neutralisant les polyomavirus | 
| EP3746138A4              (fr) | 2018-02-02 | 2021-11-03 | Alexza Pharmaceuticals, Inc. | Dispositif aérosol à condensation électrique | 
| CA3090322A1              (fr) | 2018-02-12 | 2019-08-15 | Diabetes-Free, Inc. | Anticorps monoclonaux anti-cd40 humain antagonistes ameliores | 
| MX2020009526A              (es) | 2018-03-12 | 2020-10-28 | Zoetis Services Llc | Anticuerpos anti-ngf y metodos de estos. | 
| PE20251751A1              (es) | 2018-03-29 | 2025-07-09 | Pfizer | Variantes de lfa3 y composiciones y usos de las mismas | 
| US10633458B2              (en) | 2018-04-10 | 2020-04-28 | Y-Biologics Inc. | Cell engaging binding molecules | 
| US11932681B2              (en) | 2018-05-31 | 2024-03-19 | Novartis Ag | Hepatitis B antibodies | 
| AU2019277700A1              (en) | 2018-06-01 | 2020-11-19 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use | 
| US11492409B2              (en) | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof | 
| UY38265A              (es) | 2018-06-20 | 2020-01-31 | Novartis Ag | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas | 
| EP3826659B1              (fr) | 2018-07-10 | 2024-06-19 | Rush University Medical Center | Immunomodulateur destiné à être utilisé dans le traitement d'une infection bactérienne | 
| CA3106418A1              (fr) | 2018-07-20 | 2020-01-23 | Pierre Fabre Medicament | Recepteur pour vista | 
| US20200022921A1              (en)* | 2018-07-23 | 2020-01-23 | Translate Bio, Inc. | Dry powder formulations for messenger rna | 
| KR102846109B1              (ko) | 2018-09-07 | 2025-08-18 | 화이자 인코포레이티드 | 항-αvβ8 항체 및 그의 조성물 및 용도 | 
| WO2020053742A2              (fr) | 2018-09-10 | 2020-03-19 | Novartis Ag | Anticorps peptidiques anti-hla-vhb | 
| WO2020102454A1              (fr) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Peptides ciblant le cd40 et leurs utilisations | 
| WO2020106358A1              (fr) | 2018-11-20 | 2020-05-28 | Takeda Vaccines, Inc. | Nouveaux anticorps contre le virus zika et utilisations associées | 
| KR20210102274A              (ko) | 2018-12-13 | 2021-08-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤르복시디엔 항체-약물 접합체 및 사용 방법 | 
| WO2020128863A1              (fr) | 2018-12-19 | 2020-06-25 | Novartis Ag | Anticorps anti-tnf-alpha | 
| EP4406555A3              (fr) | 2018-12-21 | 2024-11-06 | Novartis AG | Anticorps anti-pmel17 et conjugués de ceux-ci | 
| EP3911739A1              (fr) | 2019-01-16 | 2021-11-24 | University Of Rochester | Amélioration de la fonction de la barrière épithéliale ou endothéliale | 
| JP7393810B2              (ja) | 2019-03-08 | 2023-12-07 | アブティス・カンパニー・リミテッド | 部位特異的抗体コンジュゲーション及びその具体例としての抗体-薬物コンジュゲート | 
| EP3947419A4              (fr) | 2019-04-01 | 2023-05-24 | Rush University Medical Center | Réactifs et dosages utilisant des domaines d'intégrine modifiés | 
| CN119613486A              (zh) | 2019-05-20 | 2025-03-14 | 诺华股份有限公司 | 具有包含亲水性基团的接头的抗体药物缀合物 | 
| JP7404671B2              (ja)* | 2019-06-25 | 2023-12-26 | 株式会社リコー | 多孔質微粒子及びその製造方法、並びに医薬組成物 | 
| EP4041767A1              (fr) | 2019-09-26 | 2022-08-17 | StCube & Co. | Anticorps spécifiques dirigés contre ctla-4 glycosylée et leurs procédés d'utilisation | 
| CN114829404B              (zh) | 2019-10-09 | 2025-09-09 | 斯特库比公司 | 对糖基化的lag3特异的抗体及其使用方法 | 
| TWI877249B              (zh) | 2019-11-07 | 2025-03-21 | 日商衛材R&D企管股份有限公司 | 艾日布林抗體-藥物結合物及使用方法 | 
| CN115190814A              (zh) | 2020-01-24 | 2022-10-14 | 辉瑞公司 | 抗e-选择素抗体、组合物和使用方法 | 
| WO2021202463A1              (fr) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anticorps anti-rsv | 
| WO2021202473A2              (fr) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anticorps modifiés | 
| US20230181756A1              (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer | 
| CN116096758A              (zh) | 2020-05-01 | 2023-05-09 | 诺华股份有限公司 | 工程化免疫球蛋白 | 
| JP2023523760A              (ja) | 2020-05-01 | 2023-06-07 | ノバルティス アーゲー | 免疫グロブリン変異体 | 
| BR112022022986A2              (pt) | 2020-05-13 | 2023-01-17 | Disc Medicine Inc | Anticorpos anti-hemojuvelina (hjv) para tratar mielofibrose | 
| US20210371503A1              (en) | 2020-05-29 | 2021-12-02 | University Of Cologne | Neutralizing antibodies against sars-related coronavirus | 
| WO2021248005A1              (fr) | 2020-06-05 | 2021-12-09 | Eisai R&D Management Co., Ltd. | Conjugués anticorps anti-bcma-médicament et procédés d'utilisation | 
| WO2022077021A1              (fr) | 2020-10-09 | 2022-04-14 | Pfizer Inc. | Anticorps cd1a et leurs utilisations | 
| GB202017058D0              (en) | 2020-10-27 | 2020-12-09 | Kymab Ltd | Antibodies and uses thereof | 
| KR20230104651A              (ko) | 2020-11-06 | 2023-07-10 | 노파르티스 아게 | Cd19 결합 분자 및 이의 용도 | 
| AU2021374083A1              (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies | 
| US20240002509A1              (en) | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS | 
| KR20230112128A              (ko) | 2020-11-24 | 2023-07-26 | 노파르티스 아게 | 항-cd48 항체, 항체 약물 접합체 및 이의 용도 | 
| US20240383968A1              (en) | 2020-12-11 | 2024-11-21 | Boehringer Ingelheim International Gmbh | Formulation for multi-purpose application | 
| UY39610A              (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr | 
| GB202101125D0              (en) | 2021-01-27 | 2021-03-10 | Kymab Ltd | Antibodies and uses thereof | 
| CN117396502A              (zh) | 2021-02-09 | 2024-01-12 | 佐治亚大学研究基金会有限公司 | 针对肺炎球菌抗原的人类单克隆抗体 | 
| WO2022221720A1              (fr) | 2021-04-16 | 2022-10-20 | Novartis Ag | Conjugués anticorps-médicament et leurs procédés de fabrication | 
| CN118119642A              (zh) | 2021-10-28 | 2024-05-31 | 诺华股份有限公司 | 工程化Fc变体 | 
| GB202117111D0              (en) | 2021-11-26 | 2022-01-12 | Kymab Ltd | Antibodies for use as therapeutics against bacterial infections | 
| EP4190810A1              (fr) | 2021-12-01 | 2023-06-07 | Universität zu Köln | Neutralisation d'anticorps contre le coronavirus apparenté au virus du sras | 
| JP2024542793A              (ja) | 2021-12-01 | 2024-11-15 | ウニヴェルズィテート ツー ケルン | Sars関連コロナウイルスに対する中和抗体 | 
| EP4507720A1              (fr) | 2022-04-14 | 2025-02-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Alpha-1-antitrypsine pour le traitement d'infections à paramyxoviridae ou orthomyxoviridae | 
| CR20240455A              (es) | 2022-04-26 | 2024-12-20 | Novartis Ag | Anticuerpos multiespecíficos que se dirigen a il-13 e il-18 | 
| JP2025525530A              (ja) | 2022-07-15 | 2025-08-05 | ヤンセン バイオテツク,インコーポレーテツド | 抗原結合可変領域の改善された生物工学による対合のための材料及び方法 | 
| JP2025525969A              (ja) | 2022-08-05 | 2025-08-07 | ヤンセン バイオテツク,インコーポレーテツド | 脳腫瘍を治療するためのcd98結合構築物 | 
| MA71684A              (fr) | 2022-08-05 | 2025-05-30 | Janssen Biotech, Inc. | Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales | 
| WO2024127366A1              (fr) | 2022-12-16 | 2024-06-20 | Pheon Therapeutics Ltd | Anticorps dirigés contre la protéine 1 contenant le domaine cub (cdcp1) et leurs utilisations | 
| US20240294651A1              (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies | 
| WO2024175802A2              (fr) | 2023-02-24 | 2024-08-29 | Universität Zu Köln | Anticorps neutralisant le sars-cov-2 | 
| EP4484445A1              (fr) | 2023-06-26 | 2025-01-01 | Universität zu Köln | Anticorps neutralisants du hcmv | 
| WO2025003381A1              (fr) | 2023-06-28 | 2025-01-02 | Universität Zu Köln | Neutralisation d'anticorps monoclonaux humains contre p. aeruginosa |